

Synthesis of 4-Amino-5-furyl-2-yl-4H-1, 2, 4-triazole-3-thiol Derivatives as a Novel Class of Endothelin(ET) Receptor Antagonists

Xin Yong LIU*, Wen Fang XU, Jing De WU


School of Pharmacy, Shandong University, Jinan 250012

Abstract: A series of novel 3-alkylthio-4-arylideneamino-5-(2-furyl)-1, 2, 4-triazole derivatives were synthesized. Their chemical structures were confirmed with elemental analysis and spectral data. Endothelin(ET) receptor competitive binding assay showed that some compounds exhibited high selective as potent ET-1 receptor antagonist.

Keywords: 1, 2, 4-Triazole derivatives, ET antagonist.

Endothelin(ET), as a peptides family secreted from endothelial cell, plays a very important physiological role in vasoconstriction, and ET receptor antagonists attract much attention in search for novel therapeutics for the various cardiovascular diseases (CVDs)¹. 1, 2, 4-Triazole derivatives have been widely investigated due to their broad spectrum of pharmacological activities, such as antitumor², antiviral³, antibacterial^{4,5}, antifungal⁶, anti-inflammatory⁷, analgesic⁸ and antidepressant⁹. 4-Substituted amino or 3-alkylated sulfanyl-1, 2, 4-triazole derivatives were synthesized and found to be an active antibacterial agents in our previous work¹⁰. However, some 3-alkylthio-4-arylideneamino-5-(2-furyl)-1, 2, 4-triazoles have not been reported so far. Prompted by these observations and in continuing our work on biologically study of 1, 2, 4-triazole heterocycles, herein we reported the synthesis and pharmacological evaluation of the new 3, 4, 5-trisubstituted-1, 2, 4-triazole derivatives as a novel class of ET receptor antagonists.


Scheme 1



*E-mail: xinyongli@jn-public.sd.cninfo.net

Compound **1**, 4-amino-5-(2-furyl)-1, 2, 4-triazole-3-thiol, was prepared according to literature¹⁰. Compounds **2** were prepared by the alkylation of compound **1** with alkyl halide in potassium hydroxide ethanol solution (**Scheme 1**). Schiff bases **3** were obtained by the condensation of compound **1** with different aldehydes under refluxing in ethanol solution. The S-alkylation reaction of the compounds **3** was carried out in the similar manner as the preparation of compounds **2** to obtain compounds **4** (**Scheme 2**).

The structures of all synthesized compounds were confirmed on the basis of elemental analysis, ¹HNMR and IR spectra.



Synthesis of 4-(5-nitrofurylidene)amino-5-(2-furyl)-1, 2, 4-triazole-3-thiol 3a

Compound **1** (0.1 mmol) was refluxed with 5-nitro-2-furaldehyde diacetate in sulfuric acid, ethanol and water (0.1:1:2) solution for 2 h, and recrystallized from acetone/ethanol (4:1), yellow needles, yield 98.3%, mp: 198–201°C. ¹HNMR (DMSO-d₆) δ ppm: 14.39(s, 1H, NH or SH); 10.34(s, 1H, -N=CH), 8.01(d, 1H, J=1.5Hz, furan H-5'); 7.88(d, 1H, AB, J₁=3.5Hz, furan H-4''); 7.75(d, 1H, AB, J₂=3.5Hz, furan H-3''); 7.28(d, 1H, J=3.0Hz, furan H-3'); 6.78(dd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, furan H-4'). IR(KBr, cm⁻¹): 3109 (s, ν_{CH}), 2977, 2936 (w, ν_{CH}), 1623 (s, ν_{C=N}), 1536 (s, ν_{asNO2}), 1450 (s, ν_{C=C}), 1349 (s, ν_{NO2}), 1274 (s, ν_{N-N=C}), 968 (s), 721 (m, ν_{C-S-C}).

Synthesis of 4-(3,4-dimethoxyphenylidene)amino-5-(2-furyl)-1,2,4-triazole-3-thiol 3b

Compound **1** (0.1 mmol) was refluxed with 3,4-dimethoxyphenyl aldehyde (0.11 mmol) for 3 h. **3b** was recrystallized from ethanol as white needles. yield 56.1%, mp: 225–227°C. IR(KBr, cm⁻¹): 3137, 3115 (m, ν_{Ar-H}), 2963, 2933 (ν_{CH3}), 1604 (ν_{C=C}), 1275 (m, ν_{N-N=C}). Anal. calcd. For C₁₅H₁₄N₄O₃S (%): C 54.54, H 4.27, N 16.96. Found: C 54.27, H 4.13, N 17.03.

General procedure for the preparation of compounds 2 or 4

A suspension of **1** or **3** (1 mmol) in 10 mL of ethanol was added dropwise 1 mL of KOH water solution (2 mol.L⁻¹) in cooling and with vigorous stirring. While the solid was

dissolved, alkyl halide (1.2 mmol) was added dropwise. After addition, the temperature was kept at 25°C for 1-2 h, then the reaction mixture was cooled, the white precipitate was filtered, recrystallized from proper solvent.

3-Benzylthio-4-(5-nitrofurylidene)amino-5-(2-furyl)-1,2,4-triazole 4a

Recrystallized from ethanol, yellow needles, yield 66.4%, mp:159~161°C. ¹HNMR (DMSO-d₆) δ ppm: 8.82(s, 1H, =N=CH), 7.93(d, 1H, J=1.5Hz, furan H-5'), 7.83(d, 1H, AB, J₁=3.6Hz, furan H-4''), 7.65(d, 1H, AB, J₂=3.6Hz, furan H-3''), 7.34~7.22 (m, 5H, Ph-H), 7.02(d, 1H, J=3.6Hz, furan H-3'), 6.71(dd, 1H, J₁=1.5 Hz, J₂=3.6Hz, furan H-4'), 4.43(s, 1H, SCH₂). IR(KBr, cm⁻¹): 3123, 3027(w, Ar-H); 1572, 1495, 1435, 1347(s), 1275, 1255, 1014, 964, 743, 710. Anal. calcd. for C₁₅H₁₄N₄O₃S (%): C 54.68, H 3.31, N 17.71. Found: C 54.80, H 3.35, N 17.85.

3-(3-Methoxybenzyl)thio-4-(5-nitrofurylidene)amino-5-(2-furyl)-1,2,4-triazole 4b

Separated by flash column chromatography(FCC) using eluent cyclohexane/ethyl acetate(1:3), and recrystallized from ethanol/petroleum ether (bp:90°C), yellow needles, yield 49.2%, mp:77~79°C. ¹HNMR(DMSO-d₆) δ ppm: 8.82(s, 1H, =CH), 7.93(d, 1H, J=1.5Hz, furan H-5'), 7.84(d, 1H, J=4.0Hz, furan H-3''), 7.64(d, 1H, J=4.0Hz, furan H-4'), 7.16(m, 1H, Ph-H), 7.01(d, 1H, J=3.6Hz, furan H-3'), 6.87~6.82 (m, 3H, Ph-H), 6.70(dd, 1H, J₁=1.5Hz, J₂=3.6Hz, furan H-4'), 4.37(s, 2H, SCH₂), 3.65(s, 3H, OCH₃). IR(KBr, cm⁻¹): 3091(s, ν_{Ar-H}), 1532, 1492, 1441, 1349(s), 1267, 967. Anal. calcd. for C₁₅H₁₄N₄O₃S(%): C 53.52, H 3.78, N 16.42. Found: C 52.82, H 3.85, N 17.01.

3-(4-Cyanobenzyl)thio-4-(5-nitrofurylidene)amino-5-(2-furyl)-1,2,4-triazole 4c

Recrystallized from ethanol, yellow needles, yield 78%, mp: 207~209°C. ¹HNMR (DMSO-d₆) δ ppm: 8.85(s, 1H, =CH), 7.92(d, 1H, J=1.5Hz, furan H-5'), 7.84(d, 1H, J=4.0Hz, furan H-4''), 7.73(d, 2H, J=8.2Hz, Ph 2,6-2H), 7.65(d, 1H, J=4.0Hz, furan H-3''), 7.52(d, 2H, J=8.2Hz, Ph 3,5-2H), 7.01(d, 1H, J=3.6Hz, furan H-3'), 6.70(dd, 1H, J₁=1.5Hz, J₂=3.6 Hz, furan H-4'), 4.48(s, 1H, SCH₂). IR(KBr, cm⁻¹): 2226(ν_{CN}), 1531, 1436, 1349, 1272, 1021, 965, 810, 754, 738. Anal. calcd. for C₁₉H₁₂N₆O₄S(%): C 54.28, H 2.88, N 19.99. Found: C 54.40, H 2.95, N 20.10.

3-(Ethoxycarbonyl)methylthio-4-(5-nitrofurylidene)amino-5-(2-furyl)-1,2,4-triazol 4d

Recrystallized from ethanol, yellow needles, yield 80%, mp:127~129°C. ¹HNMR (DMSO-d₆) δ ppm: 8.94(s, 1H, =CH), 7.93(d, 1H, J= 1.5 Hz, furan H-5'), 7.86(d, 1H, J=3.6Hz, furan H-4''), 7.71(d, 1H, J=3.6Hz, furan H-3''), 7.06(d, 1H, J=3.0Hz, furan H-3'), 6.72(dd, 1H, J₁=1.5Hz, J₂=3.Hz, furan H-4'), 4.08(q, 2H, J=7.2Hz, OCH₂), 4.07(s, 2H, SCH₂), 1.13(t, 3H, J=7.2Hz, CH₃). IR (KBr, cm⁻¹): 1736(s, ν_{C=O}), 1530, 1442, 1349, 1307, 1278, 1188, 1028, 766. Anal. calcd. for C₁₅H₁₃N₅O₆S(%): C 46.04, H 3.35, N 17.89. Found: C45.87, H 3.39, N 18.08.

3-(2-Furyl)-4-(3,4-dimethoxyphenylidene)amino-5-benzylthio-1, 2, 4-triazole 4e

Separated by FCC, eluted with hexane/ethyl acetate(3:2), and recrystallized from ethanol, white crystals. yield 48.1%, mp:100~102°C. IR(KBr, cm⁻¹): 3100 (ν_{=CH}) ; 3025 (Ph-H), 2957, 2935(ν_{CH3}), 1598, 1576, 1513(s), 1274 (s, ν_{N=N=C}), 1138(s), 1026, 1020(s); 784, 704(ν_{C-S-C}). Anal. calcd. for C₂₂H₂₀N₄O₃S(%): C 62.84, H 4.79, N 13.32. Found: C62.96, H 4.83, N 13.28.

3-(Ethoxycarbonyl)methylthio-4-(3,4-dimethoxyphenylidene)amino-5-(2-furyl)-1,2,4-triazole 4f

Recrystallized from acetone/cyclohexane(1:1), white crystals. yield 33.4%, mp:196~199°C. ¹HNMR(DMSO-d₆) δ ppm: 8.62(s, 1H, =CH), 7.89(d, 1H, J=1.5Hz, furan H-5'), 7.31(m, 1H, Ph-H), 7.22(d, 1H, J=3.0Hz, furan H-3'), 7.01~6.86(m, 2H, Ph-H), 6.68(dd, 1H, J₁=1.5Hz, J₂=3.0Hz, furan H-4'), 4.91(s, 2H, SCH₂), 4.13(q, 2H, J=7.2Hz, OCH₂), 3.69(s, 3H, OCH₃), 3.57(s, 3H, OCH₃), 1.13(t, 3H, J=7.2Hz, CH₃).

ET receptor competitive binding assay was tested in the cell culture solution of the rat heart ventricle muscle membranes. Bosentan, an ET_{A/B} receptor antagonist, was selected as positive standard, and [¹²⁵I]ET-1 was used as ET receptor radioligand. The results are listed in **Table 1**. Compound **3a** exhibited high inhibition of 71.93%, and represented a new leading compound of ET receptor antagonist for further study.

Table 1 The results of ET receptor competitive binding assay of the compounds **1**, **2**, **3** and **4**

Compounds No.	1	2a	2b	3a	4a	4b	4d	4e	4f
Inhibition (%) ^a	16.9	-67.96 ^b	-50.24	71.93	32.76	-98.74	11.3	15.9	7.58

^aThe final concentration of tested compounds was 10⁻²mg/mL. ^bNegative values have no any real meaning.

Acknowledgment

The financial supports of this work by Shandong Natural Science Foundation and Shandong Science & Technology Bureau Foundation are gratefully acknowledged.

References

1. F. Dasgupta, A. .K. Mukherjee, N. gangahar, *Curr. Med. Chem.*, **2002**, 9, 549.
2. E. C. Kohn, L. A. Liotta, *U.S. Patent 637145 (Chem. Abstr.*, **1991**, 115, 248099).
3. A. J. Srivatava, S. Swarup, V. K. Saxena, *J. Indian Chem. Soc.*, **1991**, 68, 103.
4. Zhongyi Wang, Haoxin Shi, Haijian Shi, *J. Heterocyclic Chem.*, **2001**, 38, 335.
5. R. H. Udupi, A. Kushnoor, A. R. Bhat, *J. Indian Chem. Soc.*, **1999**, 76, 461.
6. B. S. Holla, K. N. Poojary, B. Kalluraya, P. V. Gowda. *Farmaco*, **1996**, 51, 793.
7. R. H. G. Udupi, V. Suresh, S. R. Setty, A. R. Bhat, *J. Indian Chem. Soc.*, **2000**, 77, 303.
8. Z. G. Turan, Z. .A. Kaplancikli, K. F. S. Erol, *Farmaco*. **1999**, 54, 218.
9. J. .M. Kane, M. Wdudley, S. M. Sorensen, F. P. Miller, *J. Med. Chem.*, **1988**, 31, 1253.
10. X.Y. Liu, W. F. Xu, N. Hou, *Acta Academica Med. Shandong*, **2001**, 39 (6), 112.

Received 8 October, 2002